A new study comparing the effectiveness of oral progestogens versus a levonorgestrel-releasing intrauterine system to treat women with endometrial intraepithelial neoplasia (EIN) presents data on patient outcomes compiled over 8 years, as reported in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers
Mary Marnach, MD and coauthors from Mayo Clinic, Rochester, MN, and Mayo Clinic Hospital, Phoenix, AZ, conducted a retrospective analysis to determine which treatment approach was more effective in women with EIN who either wanted to preserve their fertility and not undergo a hysterectomy or were not optimal surgical candidates. Overall, the treatments led to disease resolution in more than 80% of patients with subcategory 1 EIN and more than 60% of patients with subcategory 2 EIN. Intrauterine hormone delivery offers greater convenience and minimal adverse effects, is rapidly reversible, and provides long-term protection of the endometrial lining.
Article: Oral Progestogens Versus Levonorgestrel-Releasing Intrauterine System for Treatment of Endometrial Intraepithelial Neoplasia, Marnach Mary L., Butler Kristina A., Henry Michael R., Hutz Catherine E., Langstraat Carrie L., Lohse Christine M., & Casey Petra M., Journal of Women's Health, doi:10.1089/jwh.2016.5774, published online 30 November 2016.